Litcius/Paper detail

Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines

Vivek Naranbhai, Wilfredo F. García-Beltrán, Christina C. Chang, Cristhian Berrios Mairena, Julia Thierauf, Grace Kirkpatrick, Maristela L. Onozato, Ju Cheng, Kerri St. Denis, Evan C. Lam, Clarety Kaseke, Rhoda Tano-Menka, Diane Yang, Maia Pavlovic, Wendy Yang, Alexander Kui, Tyler E. Miller, Michael G. Astudillo, Jennifer E. Cahill, Anand S. Dighe, David J. Gregory, Mark C. Poznansky, Gaurav D. Gaiha, Alejandro B. Balazs, A. John Iafrate

2021The Journal of Infectious Diseases134 citationsDOIOpen Access PDF

Abstract

BACKGROUND: Understanding immunogenicity and effectiveness of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is critical to guide rational use. METHODS: We compared the immunogenicity of mRNA-1273, BNT-162b2, and Ad26.COV2.S in healthy ambulatory adults. We performed an inverse-variance meta-analysis of population-level effectiveness from public health reports in > 40 million individuals. RESULTS: A single dose of either mRNA vaccine yielded comparable antibody and neutralization titers to convalescent individuals. Ad26.COV2.S yielded lower antibody concentrations and frequently undetectable neutralization titers. Bulk and cytotoxic T-cell responses were higher in mRNA1273 and BNT162b2 than Ad26.COV2.S recipients. Regardless of vaccine, <50% of vaccinees demonstrated CD8+ T-cell responses. Antibody concentrations and neutralization titers increased comparably after the first dose of either vaccine, and further in recipients of a second dose. Prior infection was associated with high antibody concentrations and neutralization even after a single dose and regardless of vaccine. Neutralization of Beta, Gamma, and Delta strains were poorer regardless of vaccine. In meta-analysis, relative to mRNA1273 the effectiveness of BNT162b2 was lower against infection and hospitalization, and Ad26COV2.S was lower against infection, hospitalization, and death. CONCLUSIONS: Variation in the immunogenicity correlates with variable effectiveness of the 3 vaccines deployed in the United States.

Topics & Concepts

ImmunogenicityCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakVirologyMedicineImmunologyImmune systemOutbreakInternal medicineInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesCOVID-19 Clinical Research Studies